Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 8/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784983 | 0.95 | CCR2 (0.44) | CCR2TRPV1DRD4GAASMN1; SMN2 | |
| SCHEMBL13063644 | 0.85 | CCR2 (0.41) | CCR2DRD4GAASMN1; SMN2MCHR2 | |
| SCHEMBL3792321 | 0.83 | CCR2 (0.44) | CCR2TRPV1DRD4AKT2TACR1 | |
| SCHEMBL13063396 | 0.82 | SMN1; SMN2 (0.38) | CCR2TRPV1GAASMN1; SMN2AKT2 | |
| SCHEMBL13063696 | 0.81 | CCR2 (0.38) | CCR2DRD4GAASMN1; SMN2MCHR2 | |
| SCHEMBL3782896 | 0.80 | CCR2 (0.44) | CCR2GAASMN1; SMN2MCHR2TACR1 | |
| SCHEMBL3783825 | 0.80 | CCR2 (0.45) | CCR2DRD4GAASMN1; SMN2TACR1 | |
| SCHEMBL3039076 | 0.78 | DRD4 (0.46) | CCR2DRD4GAASMN1; SMN2MCHR2 | |
| SCHEMBL3779151 | 0.77 | CCR2 (0.44) | CCR2GAASMN1; SMN2MCHR2KCNH2 | |
| SCHEMBL13806893 | 0.77 | CCR2 (0.41) | CCR2TRPV1GAASMN1; SMN2MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | CCR2 1/4885TRPV1 97/4885DRD4 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.